The thinner the cornea, the greater the cup shallowing

Article

Patients with open-angle glaucoma and ocular hypertension with thinner corneas show significantly greater shallowing of the cup and smaller improvements of neuroretinal rim blood flow after intraocular pressure (IOP) reduction, according to a report in the November 2006 issue of Archives of Ophthalmology.

Patients with open-angle glaucoma and ocular hypertension with thinner corneas show significantly greater shallowing of the cup and smaller improvements of neuroretinal rim blood flow after intraocular pressure (IOP) reduction, according to a report in the November 2006 issue of Archives of Ophthalmology.

Mark Lesk, Ali Hafez and Denise Descovich from the University of Montreal and the Maisonneuve-Rosemont Hospital, Canada, selected 16 patient with open-angle glaucoma and 16 patients with ocular hypertension to undergo retinal tomography and scanning laser Doppler flowmetry. These were performed in one eye before at least two months after a mean 35% reduction in IOP.

The 16 patients with thinner corneas (518±32 µm) had greater reductions in mean cup depth than those 16 with thicker corneas (587±31 µm). These changes were not statistically different between the open-angle glaucoma and ocular hypertension patients. Smaller mean improvements in neuroretinal rim blood flow were seen in patients with thinner corneas than those with thicker corneas (35±80 versus 110±111 arbitrary units; p=0.04).

The authors of the study concluded that those with thinner corneas demonstrate greater shallowing of the cup, a surrogate marker for lamina cribosa development, and smaller improvements in neuroretinal rim blood flow after IOP reduction.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.